In one paragraphArticle in American journal of respiratory and critical care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Rodrigo Cantu ValadezDepartment of Physics, University of California, Berkeley, California; and.
Pauline ChuDepartment of Pathology, and.
Tianyi ZhangDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine.
Lingli WangDivision of Cardiology, Department of Pediatrics, Stanford University, Stanford, California.
Aiqin CaoDivision of Cardiology, Department of Pediatrics, Stanford University, Stanford, California.
Micheala A AldredDepartment of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.ORCID 0000-0002-7390-9181 Funding
Pulmonary Hypertension Breakthrough InitiativeR24HL123767 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ALDRED, MICHEALA A, ERZURUM, SERPIL C. · 2014 to 2017
$10.1MUnderstanding and targeting molecular and cellular events responsible for pulmonary arteriovenous malformation development, growth and regressionR01HL169787 · NHLBI · STANFORD UNIVERSITY · PI Edda Frauke Spiekerkoetter · 2023 to 2026
$2.8MDefining the cellular and molecular mechanisms driving neointimal lesion growth in pulmonary hypertensionR01HL163013 · NHLBI · STANFORD UNIVERSITY · PI KUMAR, MAYA ELISE · 2022 to 2025
$2.7MTargeting Novel BMPR2 modifiers in Pulmonary Hypertension with Repurposed DrugsR01HL128734 · NHLBI · STANFORD UNIVERSITY · PI SPIEKERKOETTER, EDDA FRAUKE · 2016 to 2020
$2.1MWhat triggers RV Fiber Re-Orientation in response to RV pressure overload, and what is its Consequence on Inter-Ventricular Decoupling?R01HL152250 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI Vitaly Kheyfets · 2023 to 2026
$1.9MUnderstanding and targeting molecular as well as structural events governing right ventricular adaptation, failure and recovery in pulmonary hypertension using repurposed drugsR01HL158868 · NHLBI · STANFORD UNIVERSITY · PI SPIEKERKOETTER, EDDA FRAUKE · 2021 to 2024
$1.7MFrancis Family Foundation Parker B Francis FellowshipNHLBI NIH HHS R01 HL128734NHLBI NIH HHS R01 HL152250NHLBI NIH HHS R01 HL158868NHLBI NIH HHS R01 HL163013NHLBI NIH HHS R01 HL169787NHLBI NIH HHS R24 HL123767NHLBI NIH HHS Tissue samples were provided by the Pulmonary HypeNIH HHS R01HL152250NIH HHS R01HL158868NIH HHS R01HL163013NIH HHS R01HL169787
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Identifiers
PMID39499865
PMCPMC11755370
What OpenQuestion holds
Textmetadata
Read underepoch 390